COVID-19 MRNA Vaccine-associated Cerebral Venous Thrombosis: Rare Adverse Event or Coincidence?

Overview

Journal Am J Hematol

Specialty Hematology

Date 2022 Oct 29

PMID 36308514

Authors

Bingwen Eugene Fan

Ryan Ruiyang Ling

Kollengode Ramanathan

Bernard Pui Lam Leung

Xin Rong Lim

Veerendra M Chadachan

Umapathi Thirugnanam

David Stegner

Tian Ming Tu

Affiliations

Soon will be listed here.

Citing Articles

Risk benefit analysis to evaluate risk of thromboembolic events after mRNA COVID-19 vaccination and COVID-19.

Tran H, Risk M, Nair G, Zhao L NPJ Vaccines. 2024; 9(1):166.

PMID: 39271677 PMC: 11399239. DOI: 10.1038/s41541-024-00960-7.

Carditis following COVID-19 vaccination: balancing the risks and benefits.

Ling R, Somani J, Ramanathan K Lancet Reg Health West Pac. 2023; 35:100765.

PMID: 37360866 PMC: 10091046. DOI: 10.1016/j.lanwpc.2023.100765.

References

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Park J, Park M, Kim H, Song T . Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database. Vaccines (Basel). 2022; 10(5). PMC: 9145068. DOI: 10.3390/vaccines10050799. View

Krzywicka K, van de Munckhof A, Zimmermann J, Bode F, Frisullo G, Karapanayiotides T . Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. Blood. 2022; 139(17):2720-2724. PMC: 9047988. DOI: 10.1182/blood.2021015329. View

Abbattista M, Martinelli I, Peyvandi F . Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. J Thromb Haemost. 2021; 19(10):2554-2558. PMC: 8420446. DOI: 10.1111/jth.15493. View

Tu T, Yi S, Koh J, Saffari S, Hoe R, Chen G . Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore. JAMA Netw Open. 2022; 5(3):e222940. PMC: 8931554. DOI: 10.1001/jamanetworkopen.2022.2940. View

Andrews N, Stowe J, Ramsay M, Miller E . Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England. Lancet Reg Health Eur. 2021; 13:100260. PMC: 8668159. DOI: 10.1016/j.lanepe.2021.100260. View

Stegner D, Gob V, Krenzlin V, Beck S, Hemmen K, Schuhmann M . Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation. Nat Cardiovasc Res. 2024; 1(2):132-141. PMC: 11358028. DOI: 10.1038/s44161-021-00017-1. View

Campello E, Simion C, Bulato C, Radu C, Gavasso S, Sartorello F . Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study. Thromb Res. 2021; 205:24-28. PMC: 8231699. DOI: 10.1016/j.thromres.2021.06.016. View

Krzywicka K, van de Munckhof A, Sanchez van Kammen M, Heldner M, Jood K, Lindgren E . Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination. Neurology. 2021; 98(7):e759-e768. DOI: 10.1212/WNL.0000000000013148. View

10.

Ogata A, Cheng C, Desjardins M, Senussi Y, Sherman A, Powell M . Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clin Infect Dis. 2021; 74(4):715-718. PMC: 8241425. DOI: 10.1093/cid/ciab465. View

11.

Fan B, Shen J, Lim X, Tu T, Chang C, Khin H . Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event. Am J Hematol. 2021; 96(9):E357-E361. PMC: 8420211. DOI: 10.1002/ajh.26272. View

12.

Lim X, Leung B, Sum C, Lim G, Chua C, Tu T . BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study. Am J Hematol. 2022; 97(4):E141-E144. PMC: 9011698. DOI: 10.1002/ajh.26462. View